Results 41 to 50 of about 49,620 (199)

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. [PDF]

open access: yes, 2009
Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality.
Sutter, G. (Gerd)   +43 more
core   +1 more source

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico

open access: yesFrontiers in Public Health, 2023
BackgroundWith the widespread transmission of the Omicron SARS-CoV-2 variant, reinfections have become increasingly common. Here, we explored the role of immunity, primary infection severity, and variant predominance in the risk of reinfection and severe
José Antonio Montes-González   +11 more
doaj   +1 more source

Cross protection to SARS-CoV-2 variants in hamsters with naturally-acquired immunity

open access: yesVirology Journal, 2023
Since SARS-CoV-2 was first reported in late 2019, multiple variations of the original virus have emerged. Each variant harbors accumulations of mutations, particularly within the spike glycoprotein, that are associated with increased viral ...
Saina Beitari   +6 more
doaj   +1 more source

Trained immunity-related vaccines: innate immune memory and heterologous protection against infections

open access: yes, 2022
The innate immune system is able to build memory-like features in response to certain infections or vaccines, resulting in enhanced responsiveness upon (re)challenge with the same or an unrelated pathogen, a phenomenon termed 'trained immunity'. Compared
Ziogas, A., Netea, M.G.
core   +1 more source

Pathogenic epitopes, heterologous immunity and vaccine design [PDF]

open access: yesNature Reviews Microbiology, 2007
Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic.
Welsh, Raymond M., Fujinami, Robert S.
openaire   +2 more sources

Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis

open access: yesThe Journal of Infectious Diseases, 2019
AbstractDevelopment of an improved tuberculosis (TB) vaccine is a high worldwide public health priority. Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, provides variable efficacy against adult pulmonary TB, but why this protection varies is unclear.
Javeed A Shah   +4 more
openaire   +3 more sources

Heterologous immunity revisited

open access: yesParasitology, 2001
Heterologous immunity, or protection by one invading organism against another across phylogenetic divides, has been recognised for decades. It was initially thought to operate largely through enhancement of phagocytosis, but this explanation became untenable when it was realised it worked extremely well against intraerythrocytic protozoa and killed ...
openaire   +2 more sources

Asymptomatic Plasmodium falciparum infections may not be shortened by acquired immunity [PDF]

open access: yes, 2015
The duration of untreated Plasmodium falciparum infections is a defining characteristic of the parasite's biology. It is not clear whether naturally acquired immunity (NAI) can shorten infections, despite the potential implications for malaria control ...
Maire, Nicolas   +10 more
core   +1 more source

Heterologous immunity between viruses

open access: yes, 2014
Immune memory responses to previously encountered pathogens can sometimes alter the immune response to and the course of infection of an unrelated pathogen by a process known as heterologous immunity.
Selin, Liisa K.   +3 more
core   +1 more source

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

open access: yesFrontiers in Immunology, 2023
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines.
Larissa Henze   +36 more
doaj   +1 more source

Home - About - Disclaimer - Privacy